This was an exploratory human proof of concept efficacy trial to investigate different dosing regimens and routes of administration for Juvidex (Mannose-6-Phosphate) to assess the feasibility of developing
Financial Results IVAX Diagnostics reported loss for the fourth quarter of 2008 was $465,000, compared with net loss of $1,892,000 for the fourth quarter of 2007. Excluding the
Diagnostic Imaging International (DIIG) and Canadian Teleradiology Services (CTS) have entered into an acquisition agreement whereby DIIG acquired all of the outstanding shares of CTS. In conjunction with
According to Meda, the Edluar contains the well-known substance zolpidem and uses Orexo’s patented sublingual tablet formulation. The collaboration agreement with Orexo entitles it to a milestone payment
This first manufacturing unit is set up, according to the European and the FDA guidelines; it allows the production of clinical batches and will allow for the manufacture
AGI Therapeutics has announced positive results in a Phase II proof of concept study of AGI-004 in the control of chemotherapy-induced diarrhea. The results showed a statistically significant
Mr Lapointe is currently CEO of Sigma-Tau Pharmaceuticals, a company engaged in the development and commercialization of medicines for patients with rare diseases. Sigma-Tau is Dor’s North American
Cook Medical, a provider of medical devices, has reported positive results from an 11-month clinical study on Biodesign, a vaginal erosion repair graft for the treatment of vaginal
For the full year 2008, NPS reported a net loss of $31.8 million, or $0.67 per diluted share, compared to a net loss of $4.28 million, or $0.09
For the fiscal year ended December 31, 2008, net income totaled $1.83 million, or $0.11 per diluted share, compared to $2.24 million, or $0.13 per diluted share, for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.